Secondary screening
Focused screening
Fluofarma has developed a panel of assays for focused secondary screening in cell-based
models of human diseases or in primary cell cultures. Our cell-based
models enable reliable, targeted screening for a specific pathology.
Example of secondary screening in neurobiology
Fluofarma developed cellular models that mimic neurodegenerative disease.
Those models are based on primary cultures of neurons grown in presence of
neurodegeneration inducers.
As shown by the Figure below, focused screenings using those models
allow the identification of drugs able to delay the neurodegeneration process
(green).

Example of secondary screening in oncology
Fluofarma has a large panel of cancer cell lines which are representative of
the major tumor types, as well as engineered cell lines overexpressing
specific targets for more focused screening.
These cell-based tools enable allow the identification of drugs which
act on a specific cancer type or a specific target.
Download
Neurobiology.pdf
Download
Oncology.pdf
Breaking news
Scientific Publication
Fluofarma is glad to announce a new scientific publication in the journal Cell Research.Publication
Fluofarma cited in a Biocompare featured article “Flow Cytometry Gets a Makeover”Press Release
Roche adopts Fluofarma’s high-content screening platform.Scientific Publication
Fluofarma is glad to announce a new scientific publication in the journal "Analytical Chemistry". ECCP 2010
Fluofarma will be attending the European Cancer Cluster Partnering 2010 in Oslo, from September 15th to 17th.BIO-Connexion Congress
Fluofarma will be attending the Bio-Connexion Congress in Paris, from October 6th to 7th.22nd EORTC-NCI-AACR symposium
Fluofarma will be exhibitor at the 22nd EORTC-NCI-AACR symposium in Berlin from November 16th to 19th.
Roche adopts Fluofarma’s platform
October 19, 2009 – Fluofarma announced today that it entered into
a multi-year agreement with Roche.
Read
More
ALL NEWS